Patents Assigned to Genentech
  • VASCULAR DISRUPTION AGENTS AND USES THEREOF
    Publication number: 20170290883
    Abstract: Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.
    Type: Application
    Filed: November 18, 2016
    Publication date: October 12, 2017
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Heteroaryl pyridone and aza-pyrodine compounds
    Patent number: 9782405
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 10, 2017
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • Crystalline forms of an estrogen receptor modulator
    Patent number: 9783503
    Abstract: Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the estrogen receptor modulator (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl) phenyl)acrylic acid. Also described are pharmaceutical compositions suitable for administration to a mammal that include the estrogen receptor modulator, and methods of using the estrogen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with estrogen receptor activity.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: October 10, 2017
    Assignee: GENENTECH, INC.
    Inventors: Nicholas D. Smith, Mark R. Herbert
  • ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20170281792
    Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 13, 2017
    Publication date: October 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, Suzanna J. SCALES, Susan D. SPENCER, Yin ZHANG
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20170283424
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
  • PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA
    Publication number: 20170283505
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Application
    Filed: June 14, 2017
    Publication date: October 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Martin GAWLITZEK, Shun LUO, Christina Teresa BEVILACQUA
  • Anti-VEGF antibodies
    Patent number: 9777059
    Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: October 3, 2017
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee
  • IMMUNOCONJUGATES COMPRISING ANTI-HER2 ANTIBODIES AND PYRROLOBENZODIAZEPINES
    Publication number: 20170274092
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 28, 2017
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
    Publication number: 20170274073
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.
    Type: Application
    Filed: March 2, 2017
    Publication date: September 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Jane GROGAN, Yuanyuan XIAO, Patrick CAPLAZI, Steve LIANOGLOU, Jason HACKNEY, Eugene Yu-Chuan CHIANG
  • ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20170275273
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Mehmet Kahraman, Steven P. Govek, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170275289
    Abstract: The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 28, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, Anthony F. Romero, Alexander M. Taylor
  • N-substituted benzamides and methods of use thereof
    Patent number: 9771376
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: September 26, 2017
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel F. Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • Therapeutic compounds and uses thereof
    Patent number: 9763922
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 19, 2017
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Harvest operations for recombinant proteins
    Patent number: 9765379
    Abstract: The present invention contemplates methods of producing a recombinant protein comprising fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: September 19, 2017
    Assignee: Genentech, Inc.
    Inventors: Michael W. Laird, Richard St. John, Jane V. Gunson, Kimberly Kaleas, Deepa Nadarajah, Rachel L E Adams, Bradley R. Snedecor
  • Serine/threonine kinase inhibitors
    Patent number: 9763942
    Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 19, 2017
    Assignees: Genentech, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
  • CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
    Publication number: 20170260253
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
    Type: Application
    Filed: November 21, 2016
    Publication date: September 14, 2017
    Applicant: Genentech, Inc.
    Inventors: Sunil Bhakta, Jagath R. Junutula
  • LOW AFFINITY BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES AND USES THEREOF
    Publication number: 20170260292
    Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.
    Type: Application
    Filed: February 17, 2017
    Publication date: September 14, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, Ryan Jefferson WATTS, Yunhua Yu ZUCHERO, Yin ZHANG
  • PRODUCTION OF HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS
    Publication number: 20170260252
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.
    Type: Application
    Filed: November 4, 2016
    Publication date: September 14, 2017
    Applicant: Genentech, Inc.
    Inventors: JUSTIN SCHEER, WHITNEY SHATZ, DOMINGOS NG
  • PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE
    Publication number: 20170252457
    Abstract: Processes are described for the preparation of F-benzoxazinorifamycin I: and intermediates for conjugation with an antibody.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 7, 2017
    Applicant: Genentech, Inc.
    Inventors: Stephan Bachmann, Serena Maria Fantasia, Michael Jansen, Stefan Koenig, Xin Linghu, Sebastian Rieth, Nathaniel L. Segraves, Andreas Zogg
  • GALACTOENGINEERED IMMUNOGLOBULIN 1 ANTIBODIES
    Publication number: 20170253661
    Abstract: The present invention relates to galactoengineered recombinant antibodies of IgG1 isotype, methods for the production of said antibodies and uses thereof.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 7, 2017
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Sebastian Malik, Dietmar Reusch, Alfred Schnüriger, Max L Tejada, Marco Thomann